CD274 and cancer: The recent successes and improved safety profiles of ICI in cancer therapy, particularly targeting programmed cell death protein 1 (PD-1) and its ligands (PD-L1/2), have resulted in approval for several solid and hematologic malignancies, even as first-line therapy [1].